FDA authorizes 4th Pfizer COVID-19 bivalent dose for certain children under 5
The Food and Drug Administration April 28 authorized a fourth Pfizer COVID-19 bivalent vaccine dose at least one month after the third dose for certain immunocompromised children aged six months through 4, and additional doses at the discretion of their health care provider. For more information, see the updated emergency use authorization and fact sheet for health care providers.
Related News Articles
Headline
Most health insurers must cover the updated COVID-19 vaccines from Pfizer and Moderna without cost sharing effective Sept. 11, when the Food and Drug…
Headline
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating…
Headline
As authorized yesterday by the Food and Drug Administration and recommended by its vaccine advisory committee, the Centers for Disease Control and Prevention…
Headline
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list…
Headline
In time for back-to-school health screenings, AHA Aug. 25 released an infographic on strategies that clinicians and the Centers for Disease Control and…
Headline
Receiving a COVID-19 mRNA vaccine or booster during pregnancy can benefit pregnant people and their newborn infants, according to findings from a federally…